WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ:WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time on April 19, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT” on April 22, 2024. At such time, the Company’s common stock will also commence trading under a new CUSIP number, 97382D 501.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.